Early Catheter Removal Does Not Increase Risk of PE
Among patients with a hematologic malignancy and central venous catheter (CVC)–associated upper extremity deep vein thrombosis (UEDVT), removing CVCs within 48 hours of diagnosis...
rFIXFc as Prophylaxis and Treatment in Pediatric Hemophilia B
Results from the phase III B-LONG study published in Blood Advances found that recombinant factor IX Fc fusion protein (rFIXFc) was an effective prophylactic...
Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL
Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia (APL) included treatment delays and the incidence of hemostatic...
Conserving Red Blood Cell Units in the Treatment of Patients With SCD During Blood...
The ongoing COVID-19 pandemic has led to severe blood shortages within the health care delivery system, disproportionately affecting the supply of red blood cells...
Oblimersen Shows No Added Benefit in Newly Diagnosed Acute Myeloid Leukemia
The addition of BCL-2 antisense oligonucleotide oblimersen to standard induction chemotherapy did not improve remission rates in older patients with newly diagnosed acute myeloid...
Polatuzumab as Bridging or Salvage Therapy for Patients With Relapsed/Refractory LBCL
Polatuzumab vedotin was approved in 2019 in combination with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma (LBCL). It showed...
Post-Transplant High-Dose Chemotherapy Increases Risk of Toxicities in Older Patients with Lymphoma
Most patients with lymphoma who are over age 60 experience cardiovascular toxicities with high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT), but these patients...
Pain, Comorbidities Increase Risk of Severe COVID-19 in Patients with SCD
Research published in Blood Advances found patients with sickle cell disease (SCD) and a history of pain and renal and heart/lung comorbidities have a...
Post-Transplant High-Dose Chemotherapy Increases Risk of Toxicities in Older Patients With Lymphoma
Most patients with lymphoma who are over age 60 experience cardiovascular toxicities with high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT), but these patients...
Idelalisib and Obinutuzumab Combination Shows Promise in Relapsed/Refractory Waldenström Macroglobulinemia
A combination regimen consisting of idelalisib and obinutuzumab led to promising response and survival rates in patients with relapsed and refractory Waldenström macroglobulinemia (WM),...
Current Issue
September 2021 Volume 7 Issue 11
This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.